A potential immunological silver bullet for COVID‐19: The trivalent chimpanzee adenoviral serotype‐68 vector (Tri:ChAd).

It is promising to design a vaccine without the vulnerabilities of first-generation vaccines and to develop a cheaper and more attractive vaccine for protection-control in the fight against COVID-19. Keywords: adenoviral vectors; mucosal immunity; next-generation vaccine; SARS-CoV-2; trained innate immunity EN adenoviral vectors mucosal immunity next-generation vaccine SARS-CoV-2 trained innate immunity 2565 2567 3 08/09/22 20220801 NES 220801 Humanity has been facing a major challenge recently from a microbe called SARS-CoV-2. For example, the respiratory mucosal immunity induced by the inhaled aerosol modified vaccinia Ankara Tuberculosis vaccine in humans was not achieved by intradermal injection of the same vaccine.6 Providing long-term protection against current and future variants and sustained vaccine-induced herd immunity is a great challenge. [Extracted from the article]